{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:35:50Z","timestamp":1790516150741,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.leukres.2016.06.002","type":"journal-article","created":{"date-parts":[[2016,6,19]],"date-time":"2016-06-19T01:03:13Z","timestamp":1466298193000},"page":"166-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"47","author":[{"given":"Magdalena","family":"Matuszak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Czy\u017c","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Kiernicka-Parulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Przyby\u0142owicz-Chalecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Jarmu\u017c-Szymczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lewandowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieczys\u0142aw","family":"Komarnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.06.002_bib0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/asheducation-2002.1.193","article-title":"Chronic lymphocytic leukemia. American Society of Hematology","author":"Kay","year":"2002","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2016.06.002_bib0010","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.06.002_bib0015","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2008.18.1701","article-title":"Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment","volume":"27","author":"Wierda","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.leukres.2016.06.002_bib0020","first-page":"183","article-title":"CLL, how many diseases?","volume":"4","author":"Hamblin","year":"2003","journal-title":"Hematol. J."},{"key":"10.1016\/j.leukres.2016.06.002_bib0025","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJMe030032","article-title":"Determining the clinical course and outcome in chronic lymphocytic leukemia","volume":"348","author":"Rai","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.06.002_bib0030","first-page":"724","article-title":"ZAP-70 expression in chronic lymphocytic leukemia: a new parameter for an old disease","volume":"88","author":"Bosch","year":"2003","journal-title":"Hematologica"},{"issue":"Suppl.10","key":"10.1016\/j.leukres.2016.06.002_bib0035","first-page":"30","article-title":"Recent update of prognosis and staging of chronic lymphocytic leukemia","volume":"88","author":"Brugiatelli","year":"2003","journal-title":"Hematology"},{"issue":"Suppl. 3","key":"10.1016\/j.leukres.2016.06.002_bib0040","first-page":"180","article-title":"Redefining prognostic elements in chronic lymphocytic leukemia","volume":"4","author":"Monserrat","year":"2003","journal-title":"Hematol. J."},{"key":"10.1016\/j.leukres.2016.06.002_bib0045","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/asheducation-2002.1.193","article-title":"Chronic lymphocytic leukemia. American Society of hematology","author":"Kay","year":"2002","journal-title":"Hematology"},{"issue":"Suppl.1","key":"10.1016\/j.leukres.2016.06.002_bib0050","first-page":"1","article-title":"The search for optimal treatment in chronic lymphocytic leukemia","volume":"34","author":"Robak","year":"2003","journal-title":"Acta Haematol. Pol."},{"key":"10.1016\/j.leukres.2016.06.002_bib0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-3-319-13150-4_6","article-title":"Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"165","author":"Sun","year":"2015","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.leukres.2016.06.002_bib0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/hon.888","article-title":"CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL","volume":"27","author":"Cro","year":"2009","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2016.06.002_bib0065","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1084\/jem.190.3.301","article-title":"Morimoto ch CD26\/dipeptidyl peptidase IV in context: the different roles of a multifunctional ectoenzyme in malignant transformation","volume":"190","author":"Iwata","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2016.06.002_bib0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/10409239309082572","article-title":"Proline-dependent structural and biological properties of peptides and proteins","volume":"28","author":"Yaron","year":"1993","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.leukres.2016.06.002_bib0075","first-page":"74","article-title":"Dipeptidyl-aminopeptidase IV (CD26) in clinical diagnosis of cutaneous T cell lymphomas","volume":"97","author":"Soko\u0142owska-Wojdy\u0142o","year":"2010","journal-title":"Przegl. Dermatol."},{"key":"10.1016\/j.leukres.2016.06.002_bib0080","first-page":"1833616","article-title":"A CD26-controlled cell surface cascade for regulation of T cell motility and chemokine signals","author":"Liu","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2016.06.002_bib0085","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00262-009-0728-1","article-title":"On the origin of serum CD26 and its altered concentration in cancer patients","volume":"58","author":"Cordero","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.leukres.2016.06.002_bib0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1600-0609.2009.01273.x","article-title":"Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia","volume":"83","author":"Molica","year":"2009","journal-title":"Eur. J. Hematol."},{"key":"10.1016\/j.leukres.2016.06.002_bib0095","doi-asserted-by":"crossref","first-page":"15044","DOI":"10.1073\/pnas.251547398","article-title":"Gene expression in papillary thyroid carcinoma reveals highly consistent profiles","volume":"98","author":"Huang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2016.06.002_bib0100","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/0167-5699(94)90316-6","article-title":"CD26: a surface protease involved in T-cell activation","volume":"15","author":"Fleisher","year":"1994","journal-title":"Immunol. Today"},{"key":"10.1016\/j.leukres.2016.06.002_bib0105","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/sj.bjc.6690167","article-title":"Constitutive expression of CD26\/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukemia","volume":"79","author":"Bauvois","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.leukres.2016.06.002_bib0110","first-page":"77","article-title":"Expression pattern of dipeptidyl peptidase IV activity and\/or structure homologues in cancer","volume":"55","author":"Kotackov\u00e1","year":"2009","journal-title":"Folia Biol. (Praha)"},{"key":"10.1016\/j.leukres.2016.06.002_bib0115","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/0046-8177(94)90098-1","article-title":"CD26\/dipeptidylpeptidase IV expression in human lymphomas is restricted to CD30-positive anaplastic large cells and a subset of T-cell non Hodgkin\u2019s lymphomas","volume":"25","author":"Carbone","year":"1994","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.leukres.2016.06.002_bib0120","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.06.002_bib0125","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/sj.leu.2403707","article-title":"Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia","volume":"19","author":"Schroers","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.06.002_bib0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hon.959","article-title":"Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukemia","volume":"29","author":"Bulian","year":"2011","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2016.06.002_bib0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0167-0115(03)00149-6","article-title":"Localization, transmission, spontaneous mutations, and variation of function of the Dpp4 (dipeptidyl-peptidase IV; CD26) gene in rats","volume":"115","author":"Karl","year":"2003","journal-title":"Regul. Pept."},{"key":"10.1016\/j.leukres.2016.06.002_bib0140","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/10428199609054782","article-title":"Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma","volume":"22","author":"Hallek","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2016.06.002_bib0145","first-page":"1732","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia","volume":"93","author":"Hallek","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.06.002_bib0150","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1200\/JCO.1994.12.10.2146","article-title":"Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia","volume":"12","author":"Reinisch","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.06.002_bib0155","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1182\/blood.V88.11.4259.4259","article-title":"Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia","volume":"88","author":"Sarfati","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.06.002_bib0160","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.06.002_bib0165","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.06.002_bib0170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V98.1.181","article-title":"CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia","volume":"98","author":"Ibrahim","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.06.002_bib0175","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia","volume":"351","author":"Rassenti","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.06.002_bib0180","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(03)15260-9","article-title":"ZAP-70 expression and prognosis in chronic lymphocytic leukemia","volume":"363","author":"Orchard","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2016.06.002_bib0185","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2007-05-092486","article-title":"Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia","volume":"111","author":"Gattei","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.06.002_bib0190","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2007.06965.x","article-title":"CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukemia: a prognostic parameter with therapeutic potential","volume":"140","author":"Shanafelt","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.06.002_bib0195","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.06.002_bib0200","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.06.002_bib0205","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1182\/blood-2007-05-092759","article-title":"Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia","volume":"111","author":"Roos","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.06.002_bib0210","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2008.399","article-title":"Telomere length is an independent predictor of survival, treatment requirement and Richter\u2019s syndrome transformation in chronic lymphocytic leukemia","volume":"23","author":"Rossi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.06.002_bib0215","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2005-04-1677","article-title":"Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia","volume":"107","author":"Binet","year":"2006","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616301345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616301345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T11:05:53Z","timestamp":1600772753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616301345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":43,"alternative-id":["S0145212616301345"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.06.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}